Comparison of the Effect of GLP-1 Receptor Agonists on Diurnal Glycemic Profiles in Patients with Diabetes

Comparison of the Effect of GLP-1 Receptor Agonists on Diurnal Glycemic Profiles in Patients with Diabetes - Comparison of Liraglutide and Exenatide Evaluated by CGM

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007097

Enrollment

Registered

2012-01-18

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin-independent Diabetes Mellitus

Interventions

Liraglutide and exenatide are subcutaneously injected continuous 2 days for each as a cross-over manner and diurnal glycemic profiles are evaluated by CGM. Additionally, C-peptide- and glucagon-respon

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.The patients with diabetes who are in hospital for glycemic control. 2.Insulin-independency needs to be confirmed in those who are undergone insulin therapy. 3.The patients who have agreed to participate in this study with an informed consent.

Exclusion criteria

Exclusion criteria: 1.The patients with serious complications 2.The patients who did not agree with this study 3.The patients with chronic kidney disease higher than stage 4 4.The patients with type 1 diabetes 5.Those who are not approved to be eligible to this study by corresponding researcher or co-researchers

Design outcomes

Primary

Measure	Time frame
Diurnal glycemic profiles, C-peptide- and glucagon-response to the meal test	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026